Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.

Charlotte E CostentinThomas DecaensAlexis LaurentJean-Charles NaultBernard PauleChristian LetoublonAlain LucianiJulien CalderaroRené AdamIvan BricaultGiuliana AmaddeoDaniel CherquiAriane MallatDidier SamuelChristophe DuvouxNathalie Ganne-CarriéFrançoise Roudot-ThoravalEric Vibert

Published in: Liver international : official journal of the International Association for the Study of the Liver (2017)

Under a propensity score analysis, the overall survival of patients with HCC and MVI undergoing surgical resection was similar to that achieved with sorafenib. We were not able to identify a patient subgroup experiencing a surgery-related improvement in survival, and quality of life was not evaluable.

Keyphrases

minimally invasive
clinical trial
free survival
study protocol
open label
phase iii